| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T24793 | ||||
| Target Name | Voltage-dependent L-type calcium channel alpha-1D subunit | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | SIPATRIGINE | Drug Info | IC50 = 3860 nM | ||
| PD-32577 | Drug Info | IC50 = 2000 nM | [1] | ||
| NILVADIPINE | Drug Info | IC50 = 1.04 nM | [2] | ||
| SNAP-5089 | Drug Info | Ki = 540 nM | [3] | ||
| CV-4093 | Drug Info | IC50 = 8.68 nM | [2] | ||
| CGS-27830 | Drug Info | IC50 = 592 nM | |||
| N,N'-Di-acenaphthen-5-yl-guanidine | Drug Info | IC50 = 1130 nM | |||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. | ||||
| REF 2 | J Med Chem. 1989 Oct;32(10):2399-406.Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. | ||||
| REF 3 | J Med Chem. 1995 May 12;38(10):1579-81.Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.